Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification
AbstractGlycolysis-related metabolic reprogramming is a central hallmark of human cancers, especially in renal cell carcinoma. However, the regulatory function of glycolytic signature in papillary RCC has not been well elucidated. In the present study, the glycolysis-immune predictive signature was constructed and validated using WGCNA, glycolysis-immune clustering analysis. PPI network of DEGs was constructed and visualized. Functional enrichments and patients’ overall survival were analyzed. QRT-PCR experiments were performed to detect hub genes’ expression and distribution, siRNA technology was used to silenc e t...
Source: European Journal of Medical Research - April 15, 2024 Category: Research Source Type: research
Familial syndromes associated with testicular and paratesticular neoplasms: a comprehensive review
AbstractA syndromic association between a subset of testicular/paratesticular neoplasms is well established. Such examples include Carney complex and large cell calcifying Sertoli cell tumor, Peutz-Jeghers syndrome and intratubular large cell hyalinizing Sertoli cell neoplasia, and VHL syndrome and clear cell papillary cystadenoma of the epididymis.However, recent studies proposed potential novel links between some testicular and paratesticular neoplasms with certain tumor syndromes. While more studies are still needed to solidify these associations, recent research suggests that a subset of Leydig cell tumors may arise in...
Source: Virchows Archiv - April 15, 2024 Category: Pathology Source Type: research
Preliminary Investigation of a Rapid and Feasible Therapeutic Drug Monitoring Method for the Real-Time Estimation of Blood Pazopanib Concentrations
AbstractPazopanib is a multi-kinase inhibitor used to treat advanced/metastatic renal cell carcinoma and advanced soft tissue tumors; however, side effects such as diarrhea and hypertension have been reported, and dosage adjustment based on drug concentration in the blood is necessary. However, measuring pazopanib concentrations in blood using the existing methods is time-consuming; and current dosage adjustments are made using the results of blood samples taken at the patient's previous hospital visit (approximately a month prior). If the concentration of pazopanib could be measured during the waiting period for a doctor ...
Source: The AAPS Journal - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Hemangioblastoma: An Uncommon Cause of Polycythemia in a Child
We report a 13-year-old girl with primarily neurological symptoms identified to be polycythemic during routine evaluation. Clinical examination and neuroimaging subsequently confirmed an intracranial space occupying lesion which was excised. Hemoglobin level normalized after tumor excision. This case report emphasizes the need for thorough systemic evaluation including central nervous system examination in children identified to be polycythemic. Keywords: CNS tumor; hemangioblastoma; polycythemia.PMID:38615229 | DOI:10.33314/jnhrc.v21i3.4160 (Source: Cell Research)
Source: Cell Research - April 14, 2024 Category: Cytology Authors: Surabhi Aryal Arun Kumar Sharma Source Type: research
Wide-Targeted Semi-Quantitative Analysis of Acidic Glycosphingolipids in Cell Lines and Urine to Develop Potential Screening Biomarkers for Renal Cell Carcinoma
In conclusion, urinary DSGb5 (d18:1/16:0) was a potential biomarker for cancer screening, which could contribute to the treatment of RCC patients.PMID:38612906 | DOI:10.3390/ijms25074098 (Source: Cancer Control)
Source: Cancer Control - April 13, 2024 Category: Cancer & Oncology Authors: Masamitsu Maekawa Tomonori Sato Chika Kanno Izumi Sakamoto Yoshihide Kawasaki Akihiro Ito Nariyasu Mano Source Type: research
Cuproptosis: A potential therapeutic target in clear cell renal cell carcinoma
Chin Med J (Engl). 2024 Apr 12. doi: 10.1097/CM9.0000000000003076. Online ahead of print.NO ABSTRACTPMID:38613200 | DOI:10.1097/CM9.0000000000003076 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - April 13, 2024 Category: General Medicine Authors: Yuetong Zhao Jie Li Xiaojie Lu Shuang Wu Yunze Xing Yaxuan Fang Bo Yang Source Type: research
Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
Pharmacol Res. 2024 Apr 11:107181. doi: 10.1016/j.phrs.2024.107181. Online ahead of print.ABSTRACTKidney cancers comprise about 3% of all new malignancies in the United States. Renal cell carcinomas (RCCs) are the most common type of renal malignancy making up about 85% of kidney cancer cases. Signs and symptoms of renal cell carcinomas can result from local tumor growth, paraneoplastic syndromes, or distant metastases. The classic triad of presentation with flank pain, hematuria, and a palpable abdominal mass occurs in fewer than 10% of patients. Most diagnoses result from incidental imaging findings (ultrasonography or a...
Source: Cell Research - April 13, 2024 Category: Cytology Authors: Robert Roskoski Source Type: research
Cuproptosis: A potential therapeutic target in clear cell renal cell carcinoma
Chin Med J (Engl). 2024 Apr 12. doi: 10.1097/CM9.0000000000003076. Online ahead of print.NO ABSTRACTPMID:38613200 | DOI:10.1097/CM9.0000000000003076 (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - April 13, 2024 Category: General Medicine Authors: Yuetong Zhao Jie Li Xiaojie Lu Shuang Wu Yunze Xing Yaxuan Fang Bo Yang Source Type: research
Timing, incidence and management of delayed bleeding after partial nephrectomy in patients at risk for recurrent, bilateral, multifocal renal tumors
CONCLUSIONS: Delayed bleeding after PN in a cohort of patients with multifocal tumors is an infrequent event, with similar rates to single tumor series. Patients should be counseled regarding timing and symptoms of delayed bleeding and multidisciplinary management with interventional radiology is critical for timely diagnosis and treatment.PMID:38614921 | DOI:10.1016/j.urolonc.2024.03.004 (Source: Urologic Oncology)
Source: Urologic Oncology - April 13, 2024 Category: Urology & Nephrology Authors: Patrick T Gomella Julie Solomon Michael Ahdoot Sandeep Gurram Amir H Lebastchi Elliot Levy Venkatesh Krishnasamy Michael T Kassin Richard Chang Bradford J Wood W Marston Linehan Mark W Ball Source Type: research
The impact of the COVID-19 pandemic on renal cancer care
ConclusionsThe COVID-19 pandemic resulted in fewer RCC diagnoses, especially T1a/T1b tumors. Treatment-related changes appeared to be limited, temporarily and in accordance with the adapted guidelines. The diagnostic delay could lead to more advanced RCCs in later years but there are no indications for this yet. (Source: World Journal of Urology)
Source: World Journal of Urology - April 13, 2024 Category: Urology & Nephrology Source Type: research
PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is associated with a high prevalence of cancer-related deaths. The survival rates of patients are significantly lower in late-stage ccRCC than in early-stage ccRCC, due ... (Source: BMC Cancer)
Source: BMC Cancer - April 13, 2024 Category: Cancer & Oncology Authors: Jun Wang, Xiaoming He, Yuanyuan Mi, Yong Q. Chen, Jie Li and Rong Wang Tags: Research Source Type: research
Pioglitazone ameliorates ischemia/reperfusion-induced acute kidney injury via oxidative stress attenuation and NLRP3 inflammasome
AbstractAcute kidney injury (AKI) induced by renal ischemia/reperfusion injury (IRI) is a severe clinical condition. ROS accumulation, antioxidant pathways deficiency, and inflammation are involved in IRI. Pioglitazone (Pio) exerts anti-inflammatory and antioxidant effects. The aim of this study was to explore the protective effects of pioglitazone against IRI-induced AKI. Pathogen-free Sprague –Dawley (SD) rats were arbitrarily divided into four groups: Sham operation group Control (CON) group, CON + Pio group, I/R + Saline group, and I/R + Pio group. In addition, HK-2 cells were subjected to hypoxia and reo...
Source: Human Cell - April 12, 2024 Category: Cytology Source Type: research
Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma
ConclusionsPBRM1 and RAD51 dual-loss ccRCC indicates superior responses to immunotherapy. Dual-loss ccRCC harbors an immune-desert microenvironment but enriched with M1 macrophages. Dual-loss ccRCC is susceptible to defective homologous recombination but possesses high chromosomal stability. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - April 12, 2024 Category: Cancer & Oncology Source Type: research
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Expert Rev Anticancer Ther. 2024 Apr 10. doi: 10.1080/14737140.2024.2341734. Online ahead of print.ABSTRACTINTRODUCTION: Immunotherapy represents a significant and essential component of renal carcinoma therapy, but the selection of an optimal regimen for an individual patient remains unclear. Despite significant improvements in therapeutic options for RCC, predictive biomarkers for immunotherapeutic agents remain elusive. Neopterin is a biomarker of cell-mediated immune response, with concentrations increased in different disorders, including cancer. High neopterin levels herald, in general, a poor prognosis.AREAS COVERED...
Source: Expert Review of Anticancer Therapy - April 10, 2024 Category: Cancer & Oncology Authors: Hana Studentova Katerina Hola Bohuslav Melichar Martina Spisarova Source Type: research
Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma
CONCLUSION: CD276 expression was significantly increased in ccRCC tissues and cells and positively correlated with patient prognosis. CD276 is a potential prognostic biomarker of ccRCC. Overall, this study provides a potential therapeutic strategy for ccRCC.PMID:38600002 | DOI:10.1016/j.urolonc.2024.03.018 (Source: Cancer Control)
Source: Cancer Control - April 10, 2024 Category: Cancer & Oncology Authors: Zhi-Yu Zhang Jian-Hao Xu Jiang-Lei Zhang Yu-Xin Lin Jun Ou-Yang Source Type: research
